Cell Impact AB TEMP

Cell Impact AB TEMP's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Cell Impact AB TEMP has 72.01M shares outstanding.

As of June 30, 2026, Cell Impact AB TEMP maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.62, indicating elevated leverage, while an interest coverage ratio of -16.80 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cell Impact AB TEMP posted a negative return on equity (ROE) of -90.35, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -69.56, reflecting losses generated across the asset base. The company generates approximately 152,776.12 in revenue per employee across its workforce of 33.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.11 indicates how many times Cell Impact AB TEMP sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cell Impact AB TEMP recorded 34,000.00 in income tax expense. The company reported a pretax loss of -125.31M and -125.35M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 7, 2026, Cell Impact AB TEMP's stock has declined approximately 88.27% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Cell Impact AB TEMP generated 5.12M in revenue and converted that into -125.35M in net income, yielding earnings per share of -2.45. EBITDA reached -49.67M, while operating income came in at -121.06M.

As of June 30, 2026, Cell Impact AB TEMP holds 424,000.00 in cash and equivalents against 13.91M in total debt, resulting in a net debt position of 5.18M. Total book value stands at 102.14M, with working capital of 26.58M providing operational flexibility.

Cell Impact AB TEMP produced -34.80M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.59M in capital expenditures, free cash flow totaled -36.40M - equivalent to -0.71 per share.

Over the twelve months ended June 30, 2026, Cell Impact AB TEMP posted a gross margin of 0.76, reflecting its pricing power and cost economics. The operating margin of -2,365.40 and net profit margin of -2,449.14 provide insight into operational efficiency.